---
title: "Coya Therapeutics Shareholders Back Board, Auditor at Meeting"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290883129.md"
description: "Coya Therapeutics shareholders approved the election of Wilbur Ross and Dieter Weinand as Class I directors and ratified Weaver and Tidwell, L.L.P. as the independent auditor at its June 25, 2026 annual meeting. These outcomes reinforce board continuity and financial oversight. While analysts maintain a 'Buy' rating with an $18 price target, TipRanks’ AI analyst rates COYA as 'Neutral' due to weak financial performance and cash burn, despite improving revenue."
datetime: "2026-06-25T21:36:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290883129.md)
  - [en](https://longbridge.com/en/news/290883129.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290883129.md)
generator: "portal-rs"
---

# Coya Therapeutics Shareholders Back Board, Auditor at Meeting

Coya Therapeutics, Inc. ( (COYA) ) just unveiled an update.

On June 25, 2026, Coya Therapeutics, Inc. held its Annual Meeting of Stockholders, where shareholders voted on the election of two Class I directors and the ratification of the company’s independent auditor for the 2026 fiscal year. Former U.S. Commerce Secretary Wilbur Ross and pharmaceutical industry executive Dieter Weinand were elected as Class I directors to serve three‑year terms, after receiving strong shareholder support.

Investors also overwhelmingly approved the appointment of Weaver and Tidwell, L.L.P. as Coya’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with nearly all votes cast in favor and minimal opposition or abstentions. The outcomes of these votes reinforce continuity in Coya’s board composition and financial oversight, signaling shareholder confidence in the company’s governance and leadership framework.

The most recent analyst rating on (COYA) stock is a Buy  
 with a $18.00 price target.  
 To see the full list of analyst forecasts on Coya Therapeutics, Inc. stock,  
 see the COYA Stock Forecast page. 

**Spark’s Take on COYA Stock**

According to Spark, TipRanks’ AI Analyst, COYA is a Neutral.

The score is primarily held back by weak financial performance driven by large losses and ongoing cash burn, despite improving revenue and low recent leverage. Technical indicators are moderately supportive and provide the main offset, while valuation remains challenged due to lack of profitability and no dividend support.

To see Spark’s full report on COYA stock,  
 click here. 

**More about Coya Therapeutics, Inc.**

Coya Therapeutics, Inc. is a biotechnology company, as indicated by its focus on scientific leadership at the executive level and the use of an independent registered public accounting firm typical of clinical-stage life sciences firms. The company is publicly traded and governed by a board of directors divided into classes with staggered multi‑year terms, reflecting a standard corporate governance structure for mid‑cap biopharma issuers.

**Average Trading Volume:** 166,961

**Technical Sentiment Signal:** Buy

**Current Market Cap:** $126.4M

Learn more about COYA stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [COYA.US](https://longbridge.com/en/quote/COYA.US.md)

## Related News & Research

- [Roth MKM Sticks to Its Buy Rating for Coya Therapeutics, Inc. (COYA)](https://longbridge.com/en/news/296711581.md)
- [CVW Sustainable Royalties shareholders voted for non-voting share class to enable $50 million Fairfax investment](https://longbridge.com/en/news/297182602.md)
- [Dror Ortho-Design announces special shareholder meeting](https://longbridge.com/en/news/297368981.md)
- [EPH Invest publishes minutes, voting report from Aug. 21 shareholder meeting](https://longbridge.com/en/news/297364872.md)
- [Spruce Power reconvened annual shareholder meeting for vote on director slate, other proposals](https://longbridge.com/en/news/297053597.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**